An anti-miR-22 drug candidate, APT-110, was shown to increase insulin sensitivity and effectively reduce hepatic steatosis in mice, suggesting the potential application in NAFLD treatment.406. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.